Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): Contribution of genotype to cognitive developmental course-Reference-Cited by-同舟云学术

Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): Contribution of genotype to cognitive developmental course

Published:2020-09 Issue: Volume:24 Page:100630
ISSN:2214-4269
Container-title:Molecular Genetics and Metabolism Reports
language:en
Short-container-title:Molecular Genetics and Metabolism Reports

Author:

Seo Joo-Hyun,Okuyama Torayuki,Shapiro Elsa,Fukuhara Yasuyuki,Kosuga Motomichi

Funder

JCR Pharmaceuticals Co., Ltd.

Publisher

Elsevier BV

Subject

Endocrinology,Genetics,Molecular Biology

Reference32 articles.

1. Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: results of a consensus procedure;van der Lee;Mol. Genet. Metab.,2017

2. Multidisciplinary management of Hunter syndrome;Muenzer;Pediatrics,2009

3. Mucopolysaccharidosis type II, Hunter’s syndrome;Tylki-Szymańska;Pediatr. Endocrinol. Rev.,2014

4. Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses;Barone;Ital. J. Pediatr.,2018

5. Natural progression of neurological disease in mucopolysaccharidosis type II;Holt;Pediatrics,2011

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase‐IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II;Journal of Inherited Metabolic Disease;2024-09-09

2. Clinical investigator perspectives on patient outcomes in children with neuronopathic mucopolysaccharidosis II during intrathecal idursulfase-IT treatment;Orphanet Journal of Rare Diseases;2024-04-12

3. Advancing clinical development for neuronopathic Hunter syndrome through a quantitatively‐driven reverse translation framework;Clinical and Translational Science;2024-03-28

4. Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan;Orphanet Journal of Rare Diseases;2024-03-07

5. Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: Final report of 5-year results from a Japanese open-label phase 1/2 study;Molecular Genetics and Metabolism;2023-12